Literature DB >> 10382877

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats.

H M Siefert1, C Kohlsdorfer, W Steinke, A Witt.   

Abstract

BAY 12-8039 (moxifloxacin-HCl) and 14C-labelled BAY 12-8039 were administered to male rats as single i.v. and oral doses of 4.6 and 5.0 mg/kg bodyweight respectively. The distribution of substance-associated radioactivity in the body was investigated by whole-body autoradiography. The concentrations of the unchanged compound in plasma, skin suction blister fluid and lung tissue were determined by HPLC. Whole-body autoradiography revealed distinctly higher concentrations of radioactivity in the gastrointestinal tract, urinary bladder and in most organs and tissues (e.g. kidneys, liver, spleen, lungs, various glands, cartilaginous tissues and in melanin-containing structures located in the eye, meninges and hair follicles of pigmented skin) than in blood. Radioactivity crossed the blood-brain barrier only to a small extent. The results show a high tissue affinity and a rapid and homogeneous distribution of radioactivity from blood to organs or tissues. No relevant difference in the distribution of radioactivity was found following i.v. and oral administration. After i.v. and oral dosing similar concentrations of the unchanged compound were determined in skin suction blister fluid and plasma. The concentrations of the unchanged compound in lung tissue were about three times higher than those in plasma following both i.v. and oral administration. The concentration-time courses for moxifloxacin in plasma and lung tissue were parallel.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382877     DOI: 10.1093/jac/43.suppl_2.61

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.

Authors:  H Stass; D Kubitza; J-G Möller; H Delesen
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

3.  Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.

Authors:  Keith M Olsen; Martha Gentry-Nielsen; Mei Yue; Mary U Snitily; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  In Vitro Efficacies, ADME, and Pharmacokinetic Properties of Phenoxazine Derivatives Active against Mycobacterium tuberculosis.

Authors:  Lloyd Tanner; Joanna C Evans; Ronnett Seldon; Audrey Jordaan; Digby F Warner; Richard K Haynes; Christopher J Parkinson; Lubbe Wiesner
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  Oral Fluoroquinolones and the Risk of Uveitis.

Authors:  Harpal Singh Sandhu; Alexander J Brucker; Liyuan Ma; Brian L VanderBeek
Journal:  JAMA Ophthalmol       Date:  2016-01       Impact factor: 7.389

6.  Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.

Authors:  Liqin Zhu; Yuan Zhang; Jianwei Yang; Yongming Wang; Jianlei Zhang; Yuanyuan Zhao; Weilin Dong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-03-10       Impact factor: 2.441

7.  Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats.

Authors:  Pedro Marín; Carlos M Cárceles; Elisa Escudero; Emilio Fernández-Varón
Journal:  Can J Vet Res       Date:  2007-01       Impact factor: 1.310

8.  Intravitreal clearance of moxifloxacin.

Authors:  Mohan N Iyer; Feng He; Theodore G Wensel; William F Mieler; Matthew S Benz; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2005

9.  Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.

Authors:  Agibothu Kupparam Hemanth Kumar; Alok Kumar; Thiruvengadam Kannan; Rakesh Bhatia; Dipti Agarwal; Santosh Kumar; Rajeshwar Dayal; Sheo Pratap Singh; Geetha Ramachandran
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

10.  The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Authors:  Md Rabiul Alam; Ellie Hershberger; Marcus J. Zervos
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.